Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Pierre-Henry Gabrielle; Vuong Nguyen; Louis Arnould; Francesco Viola; Javier Zarranz-Ventura; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark Gillies; Fight Retinal Blindness! Study Group; J. Wells; J. Landers; N. Saha; S. Lake; R. Phillips; N. Murray; L. Lim

doi:10.1016/j.oret.2022.05.008

Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Pierre-Henry Gabrielle, Vuong Nguyen, Louis Arnould, Francesco Viola, Javier Zarranz-Ventura, Daniel Barthelmes, Catherine Creuzot-Garcher, Mark Gillies, Fight Retinal Blindness! Study Group, J. Wells, J. Landers, N. Saha, S. Lake, R. Phillips, N. Murray, L. Lim

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

52 Downloads (Pure)

Abstract

Purpose: To report the estimated incidence, probability, risk factors, and 1-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVTs) of VEGF inhibitors for various retinal conditions in routine clinical practice.

Design: Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! project.

Participants: Eyes of patients starting IVTs of VEGF inhibitors (ranibizumab, aflibercept, or bevacizumab) for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion from January 1, 2006, to December 31, 2020. All eyes that developed RRD within 90 days of IVTs were defined as cases with RRD and were matched with control eyes.

Methods: Estimated incidence, probability, and hazard ratios (HRs) of RRD were measured using Poisson regression, Kaplan–Meier survival curve, and Cox proportional hazards models. Locally weighted scatterplot smoothing curves were used to compare visual acuity (VA) between cases and matched controls.

Main Outcome Measures: Estimated incidence of RRD.

Results: We identified 16 915 eyes of 13 792 patients who collectively received 265 781 IVTs over 14 years. Thirty-six eyes were reported to develop RRD over the study period. The estimated incidence (95% confidence interval [CI]) per year per 1000 patients and per 10 000 injections was 0.77 (0.54–1.07) and 1.36 (0.95–1.89), respectively. The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21–3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients with good presenting VA (HR [95% CI] = 0.85 [0.70–0.98] for every 10-letter increase in VA, P = 0.02) were at a lower risk. Neither the type of retinal disease (P = 0.52) nor the VEGF inhibitor (P = 0.09) was significantly associated with RRD risk. Cases with RRD lost 3 lines of vision on average compared with the prior RRD VA and had significantly fewer injections than matched controls over the year after the RRD.

Conclusions: Rhegmatogenous retinal detachment is a rare complication of VEGF inhibitor IVT in routine clinical practice with poor visual outcomes at 1 year.

Original language	English
Pages (from-to)	1044-1053
Number of pages	10
Journal	Ophthalmology Retina
Volume	6
Issue number	11
DOIs	https://doi.org/10.1016/j.oret.2022.05.008
Publication status	Published - Nov 2022
Externally published	Yes

Keywords

Anti-VEGF
Incidence
Intravitreal injection (IVT)
Retinal diseases
Rhegmatogenous retinal detachment (RRD)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oret.2022.05.008Licence: CC BY

Final published versionFinal published version, 1.02 MBLicence: CC BY

Cite this

Gabrielle, P.-H., Nguyen, V., Arnould, L., Viola, F., Zarranz-Ventura, J., Barthelmes, D., Creuzot-Garcher, C., Gillies, M., Fight Retinal Blindness! Study Group, Wells, J., Landers, J., Saha, N., Lake, S., Phillips, R., Murray, N., & Lim, L. (2022). Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry. Ophthalmology Retina, 6(11), 1044-1053. https://doi.org/10.1016/j.oret.2022.05.008

@article{1b617f22a58a4ad595db2c30943eda7e,

title = "Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry",

abstract = "Purpose: To report the estimated incidence, probability, risk factors, and 1-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVTs) of VEGF inhibitors for various retinal conditions in routine clinical practice. Design: Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! project.Participants: Eyes of patients starting IVTs of VEGF inhibitors (ranibizumab, aflibercept, or bevacizumab) for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion from January 1, 2006, to December 31, 2020. All eyes that developed RRD within 90 days of IVTs were defined as cases with RRD and were matched with control eyes. Methods: Estimated incidence, probability, and hazard ratios (HRs) of RRD were measured using Poisson regression, Kaplan–Meier survival curve, and Cox proportional hazards models. Locally weighted scatterplot smoothing curves were used to compare visual acuity (VA) between cases and matched controls.Main Outcome Measures: Estimated incidence of RRD. Results: We identified 16 915 eyes of 13 792 patients who collectively received 265 781 IVTs over 14 years. Thirty-six eyes were reported to develop RRD over the study period. The estimated incidence (95% confidence interval [CI]) per year per 1000 patients and per 10 000 injections was 0.77 (0.54–1.07) and 1.36 (0.95–1.89), respectively. The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21–3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients with good presenting VA (HR [95% CI] = 0.85 [0.70–0.98] for every 10-letter increase in VA, P = 0.02) were at a lower risk. Neither the type of retinal disease (P = 0.52) nor the VEGF inhibitor (P = 0.09) was significantly associated with RRD risk. Cases with RRD lost 3 lines of vision on average compared with the prior RRD VA and had significantly fewer injections than matched controls over the year after the RRD. Conclusions: Rhegmatogenous retinal detachment is a rare complication of VEGF inhibitor IVT in routine clinical practice with poor visual outcomes at 1 year.",

keywords = "Anti-VEGF, Incidence, Intravitreal injection (IVT), Retinal diseases, Rhegmatogenous retinal detachment (RRD)",

author = "Pierre-Henry Gabrielle and Vuong Nguyen and Louis Arnould and Francesco Viola and Javier Zarranz-Ventura and Daniel Barthelmes and Catherine Creuzot-Garcher and Mark Gillies and {Fight Retinal Blindness! Study Group} and D. Squirrell and J. Gilhotra and C. Brooijmans and O. Tigchelaar-Besling and A. Cohn and F. Chen and A. McGeorge and S. Welch and N. Jaross and P. Peters and R. Barry and I. McLean and T. Guillaumie and A. Miri and J. Korobelnik and M. Weber and B. Walid and S. Tick and S. Valen and A. Field and S. Wickremasinghe and C. Dayajeewa and J. Wells and R. Essex and A. Dunlop and K. Michalova and C. Ng and S. Young and G. MIMOUN and C. Generic and R. Guymer and P. Carnota and {Torres Borrego}, C. and {Dolz Marco}, R. and R. Gallego-Pinazo and {Pareja Esteban}, J. and {Garc{\'i}a Layana}, A. and M. Saenz-de-Viteri and J. Uzzan and R. Ferrier and J. Ah-Chan and L. Chow and H. Steiner and A. Amini and G. Clark and N. Wittles and P. Windle and J. Vingerling and C. Clement and A. Hunt and P. Beaumont and L. Cottee and K. Lee and H. Mack and Z. Louw and J. Lusthaus and J. Chen and J. Landers and K. Billing and N. Saha and S. Lake and D. Qatarneh and R. Phillips and M. Perks and K. Banon and M. Guarro and G. Londo{\~n}o and C. Rethati and L. Sararols and J. Suarez and {Lan Oei}, S. and S. Fraser-Bell and {Montejano Milner}, R. and C. Arruabarrena and E. Chong and S. Lal and A. Higueras and F. Ascaso and {Boned Murillo}, A. and M. D{\'i}az and {Perez Rivases}, G. and {Alforja Castiella}, S. and C. Bernal-Morales and R. Casaroli-Marano and M. Figueras-Roca and J. Izquierdo-Serra and {Moll Udina}, A. and A. Parrado-Carrillo and J. Escobar and F. Lavid and {Alvarez Gil}, M. and {Catal{\'a}n Mu{\~n}oz}, P. and {Tena Sempere}, M. and L. Cerri and F. RICCI and {Broc Iturralde}, L. and {Campos Figueroa}, P. and {G{\'o}mez S{\'a}nchez}, S. and X. Valldeperas and F. Vilaplana and E. Carre{\~n}o and {Munoz Sanz}, N. and {Ventura Abreu}, N. and {Asencio Duran}, M. and P. Calvo and J. Sanchez and {Almazan Alonso}, E. and I. Flores-Moreno and {Garcia Zamora}, M. and E. Ciancas and J. Gonzalez-Lopez and {de la Fuente}, M. and {Rodriguez Maqueda}, M. and E. Cobos and D. Lorenzo and L. Cordoves and M. Acebes and S. Aparicio-Sanchis and {Fern{\'a}ndez Hortelano}, A. and J. Zarallo-Gallardo and C. Azrak and {Pi{\~n}ero S{\'a}nchez}, A. and P. Almuina-Varela and {Garc{\'i}a Garc{\'i}a}, L. and {Salinas Mart{\'i}nez}, E. and {Castilla Marti}, M. and {Campo Gesto}, A. and {Rodriguez N{\'u}{\~n}ez}, M. and G. Furness and T. Ponsioen and G. Wilson and L. Manning and I. McAllister and Tim Isaacs and A. Invernizzi and L. Castelnovo and G. Michel and B. Wolff and J. Arnold and H. Cass and D. Chan and T. Tan and L. OToole and K. Tang and C. Chung and H. Beylerian and V. DAIEN and G. Banerjee and M. Morgan and I. Reddie and J. Ongkosuwito and F. Verbraak and R. Schlingemann and S. piermarocchi and A. Thompson and J. Game and C. Thompson and R. Chalasani and M. Chilov and A. Fung and S. Nothling and R. Chong and A. Hunyor and C. Younan and R. Barnes and D. Sharp and A. Vincent and N. Murray and S. Ah-Moye and C. Hennings and H. Mehta and P. Monaco and G. Cheung and N. Karia and D. Louis and S. Every and P. Lockie and {van Hecke}, M. and {van Lith-Verhoeven}, J. and J. Wong and J. Grigg and P. Hinchcliffe and {Diaz De Durana Santa Coloma}, E. and G. Garay-Aramburu and S. Vujosevic and {Brosa Morros}, H. and M. Daniell and A. Harper and L. Lim and J. ODay and {Velazquez Villoria}, D. and C. Hooper and N. Klaassen-Broekema and R. Smit",

year = "2022",

month = nov,

doi = "10.1016/j.oret.2022.05.008",

language = "English",

volume = "6",

pages = "1044--1053",

journal = "Ophthalmology Retina",

issn = "2468-6530",

publisher = "Elsevier Inc.",

number = "11",

}

Gabrielle, P-H, Nguyen, V, Arnould, L, Viola, F, Zarranz-Ventura, J, Barthelmes, D, Creuzot-Garcher, C, Gillies, M, Fight Retinal Blindness! Study Group, Wells, J, Landers, J, Saha, N, Lake, S, Phillips, R, Murray, N & Lim, L 2022, 'Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry', Ophthalmology Retina, vol. 6, no. 11, pp. 1044-1053. https://doi.org/10.1016/j.oret.2022.05.008

Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry. / Gabrielle, Pierre-Henry; Nguyen, Vuong; Arnould, Louis et al.
In: Ophthalmology Retina, Vol. 6, No. 11, 11.2022, p. 1044-1053.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases

T2 - Data from the Fight Retinal Blindness! Registry

AU - Gabrielle, Pierre-Henry

AU - Nguyen, Vuong

AU - Arnould, Louis

AU - Viola, Francesco

AU - Zarranz-Ventura, Javier

AU - Barthelmes, Daniel

AU - Creuzot-Garcher, Catherine

AU - Gillies, Mark

AU - Fight Retinal Blindness! Study Group

AU - Squirrell, D.

AU - Gilhotra, J.

AU - Brooijmans, C.

AU - Tigchelaar-Besling, O.

AU - Cohn, A.

AU - Chen, F.

AU - McGeorge, A.

AU - Welch, S.

AU - Jaross, N.

AU - Peters, P.

AU - Barry, R.

AU - McLean, I.

AU - Guillaumie, T.

AU - Miri, A.

AU - Korobelnik, J.

AU - Weber, M.

AU - Walid, B.

AU - Tick, S.

AU - Valen, S.

AU - Field, A.

AU - Wickremasinghe, S.

AU - Dayajeewa, C.

AU - Wells, J.

AU - Essex, R.

AU - Dunlop, A.

AU - Michalova, K.

AU - Ng, C.

AU - Young, S.

AU - MIMOUN, G.

AU - Generic, C.

AU - Guymer, R.

AU - Carnota, P.

AU - Torres Borrego, C.

AU - Dolz Marco, R.

AU - Gallego-Pinazo, R.

AU - Pareja Esteban, J.

AU - García Layana, A.

AU - Saenz-de-Viteri, M.

AU - Uzzan, J.

AU - Ferrier, R.

AU - Ah-Chan, J.

AU - Chow, L.

AU - Steiner, H.

AU - Amini, A.

AU - Clark, G.

AU - Wittles, N.

AU - Windle, P.

AU - Vingerling, J.

AU - Clement, C.

AU - Hunt, A.

AU - Beaumont, P.

AU - Cottee, L.

AU - Lee, K.

AU - Mack, H.

AU - Louw, Z.

AU - Lusthaus, J.

AU - Chen, J.

AU - Landers, J.

AU - Billing, K.

AU - Saha, N.

AU - Lake, S.

AU - Qatarneh, D.

AU - Phillips, R.

AU - Perks, M.

AU - Banon, K.

AU - Guarro, M.

AU - Londoño, G.

AU - Rethati, C.

AU - Sararols, L.

AU - Suarez, J.

AU - Lan Oei, S.

AU - Fraser-Bell, S.

AU - Montejano Milner, R.

AU - Arruabarrena, C.

AU - Chong, E.

AU - Lal, S.

AU - Higueras, A.

AU - Ascaso, F.

AU - Boned Murillo, A.

AU - Díaz, M.

AU - Perez Rivases, G.

AU - Alforja Castiella, S.

AU - Bernal-Morales, C.

AU - Casaroli-Marano, R.

AU - Figueras-Roca, M.

AU - Izquierdo-Serra, J.

AU - Moll Udina, A.

AU - Parrado-Carrillo, A.

AU - Escobar, J.

AU - Lavid, F.

AU - Alvarez Gil, M.

AU - Catalán Muñoz, P.

AU - Tena Sempere, M.

AU - Cerri, L.

AU - RICCI, F.

AU - Broc Iturralde, L.

AU - Campos Figueroa, P.

AU - Gómez Sánchez, S.

AU - Valldeperas, X.

AU - Vilaplana, F.

AU - Carreño, E.

AU - Munoz Sanz, N.

AU - Ventura Abreu, N.

AU - Asencio Duran, M.

AU - Calvo, P.

AU - Sanchez, J.

AU - Almazan Alonso, E.

AU - Flores-Moreno, I.

AU - Garcia Zamora, M.

AU - Ciancas, E.

AU - Gonzalez-Lopez, J.

AU - de la Fuente, M.

AU - Rodriguez Maqueda, M.

AU - Cobos, E.

AU - Lorenzo, D.

AU - Cordoves, L.

AU - Acebes, M.

AU - Aparicio-Sanchis, S.

AU - Fernández Hortelano, A.

AU - Zarallo-Gallardo, J.

AU - Azrak, C.

AU - Piñero Sánchez, A.

AU - Almuina-Varela, P.

AU - García García, L.

AU - Salinas Martínez, E.

AU - Castilla Marti, M.

AU - Campo Gesto, A.

AU - Rodriguez Núñez, M.

AU - Furness, G.

AU - Ponsioen, T.

AU - Wilson, G.

AU - Manning, L.

AU - McAllister, I.

AU - Isaacs, Tim

AU - Invernizzi, A.

AU - Castelnovo, L.

AU - Michel, G.

AU - Wolff, B.

AU - Arnold, J.

AU - Cass, H.

AU - Chan, D.

AU - Tan, T.

AU - OToole, L.

AU - Tang, K.

AU - Chung, C.

AU - Beylerian, H.

AU - DAIEN, V.

AU - Banerjee, G.

AU - Morgan, M.

AU - Reddie, I.

AU - Ongkosuwito, J.

AU - Verbraak, F.

AU - Schlingemann, R.

AU - piermarocchi, S.

AU - Thompson, A.

AU - Game, J.

AU - Thompson, C.

AU - Chalasani, R.

AU - Chilov, M.

AU - Fung, A.

AU - Nothling, S.

AU - Chong, R.

AU - Hunyor, A.

AU - Younan, C.

AU - Barnes, R.

AU - Sharp, D.

AU - Vincent, A.

AU - Murray, N.

AU - Ah-Moye, S.

AU - Hennings, C.

AU - Mehta, H.

AU - Monaco, P.

AU - Cheung, G.

AU - Karia, N.

AU - Louis, D.

AU - Every, S.

AU - Lockie, P.

AU - van Hecke, M.

AU - van Lith-Verhoeven, J.

AU - Wong, J.

AU - Grigg, J.

AU - Hinchcliffe, P.

AU - Diaz De Durana Santa Coloma, E.

AU - Garay-Aramburu, G.

AU - Vujosevic, S.

AU - Brosa Morros, H.

AU - Daniell, M.

AU - Harper, A.

AU - Lim, L.

AU - ODay, J.

AU - Velazquez Villoria, D.

AU - Hooper, C.

AU - Klaassen-Broekema, N.

AU - Smit, R.

PY - 2022/11

Y1 - 2022/11

N2 - Purpose: To report the estimated incidence, probability, risk factors, and 1-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVTs) of VEGF inhibitors for various retinal conditions in routine clinical practice. Design: Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! project.Participants: Eyes of patients starting IVTs of VEGF inhibitors (ranibizumab, aflibercept, or bevacizumab) for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion from January 1, 2006, to December 31, 2020. All eyes that developed RRD within 90 days of IVTs were defined as cases with RRD and were matched with control eyes. Methods: Estimated incidence, probability, and hazard ratios (HRs) of RRD were measured using Poisson regression, Kaplan–Meier survival curve, and Cox proportional hazards models. Locally weighted scatterplot smoothing curves were used to compare visual acuity (VA) between cases and matched controls.Main Outcome Measures: Estimated incidence of RRD. Results: We identified 16 915 eyes of 13 792 patients who collectively received 265 781 IVTs over 14 years. Thirty-six eyes were reported to develop RRD over the study period. The estimated incidence (95% confidence interval [CI]) per year per 1000 patients and per 10 000 injections was 0.77 (0.54–1.07) and 1.36 (0.95–1.89), respectively. The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21–3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients with good presenting VA (HR [95% CI] = 0.85 [0.70–0.98] for every 10-letter increase in VA, P = 0.02) were at a lower risk. Neither the type of retinal disease (P = 0.52) nor the VEGF inhibitor (P = 0.09) was significantly associated with RRD risk. Cases with RRD lost 3 lines of vision on average compared with the prior RRD VA and had significantly fewer injections than matched controls over the year after the RRD. Conclusions: Rhegmatogenous retinal detachment is a rare complication of VEGF inhibitor IVT in routine clinical practice with poor visual outcomes at 1 year.

AB - Purpose: To report the estimated incidence, probability, risk factors, and 1-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVTs) of VEGF inhibitors for various retinal conditions in routine clinical practice. Design: Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! project.Participants: Eyes of patients starting IVTs of VEGF inhibitors (ranibizumab, aflibercept, or bevacizumab) for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion from January 1, 2006, to December 31, 2020. All eyes that developed RRD within 90 days of IVTs were defined as cases with RRD and were matched with control eyes. Methods: Estimated incidence, probability, and hazard ratios (HRs) of RRD were measured using Poisson regression, Kaplan–Meier survival curve, and Cox proportional hazards models. Locally weighted scatterplot smoothing curves were used to compare visual acuity (VA) between cases and matched controls.Main Outcome Measures: Estimated incidence of RRD. Results: We identified 16 915 eyes of 13 792 patients who collectively received 265 781 IVTs over 14 years. Thirty-six eyes were reported to develop RRD over the study period. The estimated incidence (95% confidence interval [CI]) per year per 1000 patients and per 10 000 injections was 0.77 (0.54–1.07) and 1.36 (0.95–1.89), respectively. The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21–3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients with good presenting VA (HR [95% CI] = 0.85 [0.70–0.98] for every 10-letter increase in VA, P = 0.02) were at a lower risk. Neither the type of retinal disease (P = 0.52) nor the VEGF inhibitor (P = 0.09) was significantly associated with RRD risk. Cases with RRD lost 3 lines of vision on average compared with the prior RRD VA and had significantly fewer injections than matched controls over the year after the RRD. Conclusions: Rhegmatogenous retinal detachment is a rare complication of VEGF inhibitor IVT in routine clinical practice with poor visual outcomes at 1 year.

KW - Anti-VEGF

KW - Incidence

KW - Intravitreal injection (IVT)

KW - Retinal diseases

KW - Rhegmatogenous retinal detachment (RRD)

UR - http://www.scopus.com/inward/record.url?scp=85133260697&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2022.05.008

DO - 10.1016/j.oret.2022.05.008

M3 - Article

C2 - 35589075

AN - SCOPUS:85133260697

SN - 2468-6530

VL - 6

SP - 1044

EP - 1053

JO - Ophthalmology Retina

JF - Ophthalmology Retina

IS - 11

ER -

Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this